인간 및 동물 건강용 감염 관리 시장 : 제품 유형별(소독 제품, 개인보호구, 멸균 장비), 감염 유형별, 최종사용자별 예측(-2032년)

Global Infection Control for the Human and Animal Health Market Research Report Information by Product (Disinfection Products [Liquid Disinfectants, Disinfectant Wipes, Disinfectant Sprays, and Others], Personal Protective Equipment (PPE) [Gloves, Masks, Gowns, Protective Eyewear, and Others], and Sterilization Equipment [Heat Sterilization Equipment, Low-temperature Sterilization Equipment, Radiation Sterilization Equipment, and Filtration Sterilization Equipment]), by Infection Type (Viral, Bacterial, Parasitic, and Fungal Infections), by End Us (Human Healthcare Facilities and Animal Healthcare facilities)- Forecast to 2032

Market Overview

The Infection Control for Human and Animal Health Market industry is expected to increase from USD 9.56 billion in 2023 to USD 20.95 billion by 2032, with a compound yearly growth rate (CAGR) of 8.16% over the forecast period (2023-2032).

The rising prevalence of infectious diseases is a major driver of infection control in the human and animal health markets. In recent years, there has been a significant increase in the frequency of numerous infectious diseases around the world, resulting in increased demand for infection control products and methods.

Rising awareness of infection control techniques is a key driver for the human and animal health markets. The recent pandemics and global health crises have heightened public and professional awareness of the necessity of infection prevention. Increased media coverage, educational campaigns, and government measures have all contributed to a better knowledgeable public and healthcare community. Individuals and healthcare professionals alike understand the need of disinfection products, personal protective equipment (PPE), and sterilizing equipment in preventing the spread of infectious diseases. The rising emphasis on infection control practices in many contexts, including hospitals, clinics, and public areas, has resulted in an increase in demand for innovative and effective infection control systems.

Market Segment insights

The Infection Control for Human and Animal Health Market is divided into three product categories: disinfection, personal protective equipment (PPE), and sterilization.

The market has been divided into four types of infections: viral, bacterial, parasitic, and fungal.

The market is divided into two segments based on end users: human healthcare facilities and animal healthcare facilities.

Regional insights

North America had the biggest market share of more than 33.75% in 2022, owing to the region's sophisticated healthcare infrastructure, tight regulations, high awareness of infection control measures, and increasing number of surgical procedures. PPE is often used in orthopedic surgery to avoid infections in both patients and healthcare staff. According to the American Joint Replacement Registry's annual report for 2021, 2,244,587 hip and knee operations were conducted.

Europe's infection control market for human and animal health is expected to rise significantly during the forecast year, 2022-2023, due to an increase in infection cases across Europe. The infection control industry in Europe, which includes both human and animal health, is seeing a significant spike, driven by increased awareness of infectious illnesses and the demand for better preventive measures. According to the World Health Organization, on June 26, 2023, Croatia, Italy, Spain, Sweden, and the United Kingdom of Great Britain and Northern Ireland reported an increase in confirmed cases of E-11 infection in neonates and babies, with substantial morbidity and death.

The Asia-Pacific area is a vibrant and diversified market for infection control in human and animal health. With a fast-growing population, more urbanization, and rising awareness of healthcare standards, there is a greater need for effective infection prevention and control strategies. According to the United Nations Population Fund (UNFPA), Asia and the Pacific make up 60% of the world's population, or around 4.3 billion people.

Major Players

Advanced Sterilization Products (US), STERIS plc (Ireland), Getinge AB (Sweden), Virox Technologies, Inc. (Canada), 3M (US), Zoetis Animal Healthcare (US), PeproTech Sciences Inc (Canada), Neogen Corporation (US), Cardinal Health (US), and Stryker (US) are among the key players in the Infection Control for Human and Animal Health Market.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1 DEFINITION
• 1.2 SCOPE OF THE STUDY
• 1.3 RESEARCH OBJECTIVE
• 1.4 MARKET STRUCTURE

2 RESEARCH METHODOLOGY

• 2.1 OVERVIEW
• 2.2 DATA FLOW
  • 2.2.1 DATA MINING PROCESS
• 2.3 PURCHASED DATABASE:
• 2.4 SECONDARY SOURCES:
  • 2.4.1 SECONDARY RESEARCH DATA FLOW:
• 2.5 PRIMARY RESEARCH:
  • 2.5.1 PRIMARY RESEARCH DATA FLOW:
  • 2.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
• 2.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 2.6.1 REVENUE ANALYSIS APPROACH
• 2.7 DATA FORECASTING
  • 2.7.1 DATA FORECASTING TECHNIQUE
• 2.8 DATA FORMULATIONLING
  • 2.8.1 MICROECONOMIC FACTOR ANALYSIS:
  • 2.8.2 DATA FORMULATIONLING:
• 2.9 TEAMS AND ANALYST CONTRIBUTION

3 MARKET DYNAMICS

• 3.1 INTRODUCTION
• 3.2 DRIVERS
  • 3.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES
  • 3.2.2 RISING AWARENESS OF INFECTION CONTROL MEASURES
• 3.3 RESTRAINTS
  • 3.3.1 COST CONSTRAINTS IN INFECTION CONTROL
• 3.4 OPPORTUNITY
  • 3.4.1 GROWING DEMAND FOR TECHNOLOGICALLY ADVANCED AND SUSTAINABLE INFECTION CONTROL SOLUTIONS

4 MARKET FACTOR ANALYSIS

• 4.1 VALUE CHAIN ANALYSIS
  • 4.1.1 R&D
  • 4.1.2 MANUFACTURING
  • 4.1.3 DISTRIBUTION AND SALES
  • 4.1.4 POST-SALES MONITORING
• 4.2 PORTER'S FIVE FORCES MODEL
  • 4.2.1 THREAT OF NEW ENTRANTS
  • 4.2.2 BARGAINING POWER OF SUPPLIERS
  • 4.2.3 THREAT OF SUBSTITUTES
  • 4.2.4 BARGAINING POWER OF BUYERS
  • 4.2.5 INTENSITY OF RIVALRY
• 4.3 IMPACT OF COVID-19 ON THE GLOBAL INFECTION CONTROL FOR THE HUMAN AND ANIMAL HEALTH MARKET
  • 4.3.1 IMPACT ON SUPPLY CHAIN
  • 4.3.2 IMPACT ON MARKET PLAYERS

5 GLOBAL INFECTION CONTROL FOR THE HUMAN AND ANIMAL HEALTH MARKET, BY PRODUCT

• 5.1 OVERVIEW
• 5.2 DISINFECTION PRODUCTS
  • 5.2.1 LIQUID DISINFECTANTS
  • 5.2.2 DISINFECTANT WIPES
  • 5.2.3 DISINFECTANT SPRAYS
  • 5.2.4 OTHERS
• 5.3 PERSONAL PROTECTIVE EQUIPMENT (PPE)
  • 5.3.1 GLOVES
  • 5.3.2 MASKS
  • 5.3.3 GOWNS
  • 5.3.4 PROTECTIVE EYEWEAR
  • 5.3.5 OTHERS
• 5.4 STERILIZATION EQUIPMENT
  • 5.4.1 HEAT STERILIZATION EQUIPMENT
  • 5.4.2 LOW-TEMPERATURE STERILIZATION EQUIPMENT
  • 5.4.3 RADIATION STERILIZATION EQUIPMENT
  • 5.4.4 FILTRATION STERILIZATION EQUIPMENT
  • 5.4.5 OTHERS

6 GLOBAL INFECTION CONTROL FOR THE HUMAN AND ANIMAL HEALTH MARKET, BY INFECTION TYPE

• 6.1 OVERVIEW
• 6.2 VIRAL
• 6.3 BACTERIAL
• 6.4 PARASITIC
• 6.5 FUNGAL INFECTIONS

7 GLOBAL INFECTION CONTROL FOR THE HUMAN AND ANIMAL HEALTH MARKET, BY END USER

• 7.1 OVERVIEW
• 7.2 HUMAN HEALTHCARE FACILITIES
  • 7.2.1 HOSPITALS & CLINICS
  • 7.2.2 AMBULATORY SURGICAL CENTERS
  • 7.2.3 OTHERS
• 7.3 ANIMAL HEALTHCARE FACILITIES
  • 7.3.1 VETERINARY HOSPITALS
  • 7.3.2 ANIMAL SHELTERS
  • 7.3.3 FARMING FACILITIES
  • 7.3.4 OTHERS

8 GLOBAL INFECTION CONTROL FOR THE HUMAN AND ANIMAL HEALTH MARKET, BY REGION

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 US
  • 8.2.2 CANADA
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 FRANCE
  • 8.3.3 UK
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA-PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 INDIA
  • 8.4.3 JAPAN
  • 8.4.4 AUSTRALIA
  • 8.4.5 SOUTH KOREA
  • 8.4.6 REST OF ASIA-PACIFIC
• 8.5 REST OF THE WORLD
  • 8.5.1 REST OF THE WORLD
  • 8.5.2 MIDDLE EAST & AFRICA
  • 8.5.3 SOUTH AMERICA

9 COMPETITIVE LANDSCAPE

• 9.1 INTRODUCTION
• 9.2 MARKET SHARE ANALYSIS,
• 9.3 COMPETITOR DASHBOARD
• 9.4 PUBLIC PLAYERS STOCK SUMMARY
• 9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.6.1 PRODUCT LAUNCH

10 COMPANY PROFILE

• 10.1 3M
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 SWOT ANALYSIS
  • 10.1.6 KEY STRATEGIES
• 10.2 ZOETIS ANIMAL HEALTHCARE
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 SWOT ANALYSIS
  • 10.2.6 KEY STRATEGIES
• 10.3 PEROTECH SCIENCES INC.
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 STERIS PLC
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 PRODUCTS OFFERED
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 SWOT ANALYSIS
  • 10.4.6 KEY STRATEGY
• 10.5 GETINGE AB
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 PRODUCTS OFFERED
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 SWOT ANALYSIS
  • 10.5.6 KEY STRATEGY
• 10.6 VIROX TECHNOLOGIES, INC.
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 PRODUCTS OFFERED
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 KEY STRATEGIES
• 10.7 ADVANCED STERILIZATION PRODUCTS
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 PRODUCTS OFFERED
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 KEY STRATEGIES
• 10.8 NEOGEN CORPORATION
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 SWOT ANALYSIS
  • 10.8.6 KEY STRATEGIES
• 10.9 CARDINAL HEALTH
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 KEY STRATEGIES
• 10.10 STRYKER
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 PRODUCTS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 KEY STRATEGIES

11 DATA CITATIONS